Menu of Partner Assays for the BD MAX™ System Continues to Expand in Europe

 Menu of Partner Assays for the BD MAX™ System Continues to Expand in Europe

  PR Newswire

  BALTIMORE and LIEGE, Belgium, June 24, 2013



-- New, Fully Automated Diagenode Bordetella pertussis/parapertussis Assay
Validated for Use on the BD MAX ™ System

BALTIMORE and LIEGE, Belgium, June 24, 2013 /PRNewswire/ -- BD Diagnostics, a
segment of global medical technology company BD (Becton, Dickinson and
Company), and Diagenode SA, an international biotech company based in Belgium,
announced today the European-only launch of the Diagenode Bordetella
pertussis/parapertussis real-time polymerase chain reaction (PCR) kit for use
on the BD MAX™ System. The Diagenode Bordetella pertussis/parapertussis
real-time PCR kit has been CE-marked and validated to run on the BD MAX™
System using the BD MAX™ ExK™ DNA-1 Extraction Kit, an open system reagent.
The BD MAX™ System is a fully automated system that standardizes the
extraction process and offers ease-of-use and improved laboratory workflow for
customers.

Bordetella pertussis is responsible for 30-50 million cases yearly of the
highly contagious respiratory disease commonly referred to as pertussis or
"whooping cough."[i] Timely detection through PCR is essential in preventing
the spread of disease and reducing the risk of widespread outbreaks. PCR
testing is ideal in enabling the prompt differential diagnosis of pertussis
from other respiratory diseases such as atypical pneumonia, bronchitis or
respiratory viruses.

"There is a need to rapidly address the outbreak issues associated with
whooping cough in both pediatric and adult cases," said Gregory Meehan, Vice
President, Product Planning, BD Diagnostics – Diagnostic Systems. "The
Bordetella pertussis/parapertussis real-time PCR kit expands the
syndrome-specific menu offering through our partner assays with a test that is
timely and highly relevant in meeting the market need."

The disease most commonly affects infants and young children and can be fatal
especially in infants less than one year of age; adults may also be affected.
Older children and adults with waning natural or vaccine-induced immunity, in
contrast, present with a more diverse spectrum of symptoms that necessitate
testing to establish a definitive diagnosis.

Bordetella parapertussis infection is similar to, but milder and of shorter
duration than, infection associated with B. pertussis .[ii] Approximately 40
percent of persons with B. parapertussis infection are asymptomatic.[iii]
Persons in all age groups can be infected by B. parapertussis and experience
illness; however, parapertussis occurs most frequently among children under 10
years of age.[iv]

Through collaborations with leading in vitro diagnostic (IVD) developers such
as Diagenode, BD is rapidly expanding the molecular testing menu by offering
syndrome specific and clinically relevant IVD assays across a number of
disease syndromes. "The Diagenode Bordetella pertussis/parapertussis real-time
PCR kit adds a significant assay to the BD MAX™ System that truly builds on
the flexibility and versatility of the platform, which when coupled with the
open system reagents, facilitates the rapid development of molecular testing
assays," stated Didier Allaer, CEO of Diagenode.

The expanding BD MAX™ System menu and open capability, full automation and
standardized workflow, will enable laboratories to consolidate and standardize
a broad range of molecular tests to build programs that meet both their
current and future clinical needs.

About BD BD is a leading global medical technology company that develops,
manufactures and sells medical devices, instrument systems and reagents. The
Company is dedicated to improving people's health throughout the world. BD is
focused on improving drug delivery, enhancing the quality and speed of
diagnosing infectious diseases and cancers, and advancing research, discovery
and production of new drugs and vaccines. BD's capabilities are instrumental
in combating many of the world's most pressing diseases. Founded in 1897 and
headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000
associates in more than 50 countries throughout the world. The Company serves
healthcare institutions, life science researchers, clinical laboratories, the
pharmaceutical industry and the general public. For more information, please
visit www.bd.com .

About Diagenode Diagenode ( http://www.diagenodediagnostics.com ) is a leading
developer and marketer of innovative life-science tools and systems for
epigenetics and molecular diagnostics. Diagenode is developing novel products
for the infectious disease diagnostic market, but is also providing a complete
solution for epigenetics research. Diagenode's customers include leading
epigenetics researchers, academic institutions, molecular diagnostics,
pharmaceutical and biotechnology companies. Diagenode's products provide
customers with the best quality and performance and allow scientists to
produce consistent, cost-effective and robust results.

[i] http://www.itc.nl/library/papers_2012/msc/gfm/netsanet.pdf
[ii] http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6128a1.htm
[iii] http://www.medscape.com/viewarticle/482815_3
[iv] http://www.dhs.wisconsin.gov/immunization/pdf/parapertussis.pdf

Contacts:
JamieYacco         Jean-Marie Hoornaert
BD Public Relations Diagenode Sales and Marketing
+1-201-847-4796     +32-4-364-20-50
Jamie_Yacco@bd.com  jean-marie.hoornaert@diagenode.com

Website: http://www.bd.com